Current Trials

Two trials studying the efficacy and safety of an innovative oral medication used in the treatment of Psoriatic Arthritis. One study is for patients who have never been treated with biologic medications (Treatment Naiive) and one for patients who have (Treatment Experienced)

• Treatment Naiive
  • Diagnosed with psoriatic arthritis for at least 6 months
  • Have taken medications such as methotrexate, sulfasalazine or leflunomide but symptoms did not fully resolve
  • Have tender and swollen joints
  • Have NOT taken biologic DMARDs
• Treatment Experienced
  • Have been diagnosed with Psoriatic Arthritis for at least 6 months
  • Have tender and swollen joints
  • Have taken biologic medications such as adalimumab, etanercept or secukinumab but symptoms did not completely resolve

There are a number of Clinical Research Trials enrolling in Ulcerative Colitis. They range from the study of innovative oral and injectable medications to further evaluation of some which are currently approved by Health Canada. Some trials require the patient to be biologic treatment naive but most involve patients who have already been treated with medications such as infliximab and adalimumab.

Phase IV

• A dose optimization study comparing standard dosing of an approved IV biologic with an escalated dosing protocol to achieve significant improvement/remission
  • Diagnosed for at least 1 month with Ulcerative Colitis
  • Have had inadequate response to steroids, infliximab or adalimumab OR immunosuppressants

Phase III

• A study with an innovative intravenous medication for those who have failed standard treatment for Ulcerative Colitis. Twelve week placebo arm during which those with no improvement are offered treatment with the active medication. 3:1 study medication to placebo. Open label study following completion of parent study.

Phase III

• A study comparing two doses of investigational medication administered subcutaneously to placebo for 12 weeks. Patients responding to medication will be re-randomized to a second study with the same investigational medication. Those who respond will continue; those who do not respond will be offered open-label (active) medication. Total potential time frame to completion of study 64 weeks

Phase III

• Eight week study with an investigational oral medication versus placebo.
• Patients who respond will continue on treatment for 52 weeks
• Patient who do not respond will be administered open label study medication for 8 more weeks and if at that time there is response the patient will continue on open label for 52 more weeks. If there is no response the patient will be discontinued.
• There is an open label study following completion if there is continued response